Conclusions
Patients with recurrent vasovagal syncope frequently display mild to moderate psychiatric disorders, and the presence of psychiatric illness seem to predict the risk of recurrence. Thus, in our opinion, psychiatric evaluation should be included in the clinical management of patients with severe vasovagal syncope, because it may be valuable in identifying which subjects are at high risk of recurrence and really need long-term treatment. Psychiatric and psychological interventions seem to represent a promising treatment, at least in patients with refractory vasovagal syncope and in those with blood/injury phobia. However, before becoming a first-line therapy for most vasovagal fainters, the positive effects of psychiatric treatment need to be verified in larger, randomised and placebo-controlled trials.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Brignole M, Alboni P, Benditt DG et al (2004) Guidelines on management (diagnosis and treatment) of syncope — update 2004. Europace 6:467–537
Schmidt RT (1975) Personality and fainting. J Psychosom Res 19:21–25
Sledge WH (1978) Antecedent psychological factors in the onset of vasovagal syncope. Psychosom Med 40:568–579
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM-IV). American Psychiatric Association, Washington DC, p 20
Sheldon R, Rose S, Flanagan P et al (1996) Risk factors for syncope recurrence after a positive tilt-table test in patients with syncope. Circulation 93:973–981
Di Girolamo E, Di Iorio C, Sabatini P et al (1999) Effects of paroxetine hydrochloride, a selective serotonin re-uptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 33:1227–1230
Kapoor WN, Fortunato M, Hanusa BH et al (1995) Psychiatric illnesses in patients with syncope. Am J Med 99:505–512
Linzer M, Felder A, Hackel A et al (1990) Psychiatric syncope: a new look at an old disease. Psychosomatics 31:181–188
Koenig D, Linzer M, Pontinen M et al (1992) Syncope in young adults: evidence for combined medical and psychiatric approach. J Intern Med 232:169–176
Kouakam C, Lacroix D, Baux P et al (1996) Anxiety neurosis and unexplained syncope of presumed vaso-vagal origin. Arch Mal Coeur 89:1247–1254
Cohen TJ, Thayapran N, Ibrahim B et al (2000) An association between anxiety and neurocardiogenic syncope during head-up tilt table testing. Pacing Clin Electrophysiol 23:837–841
Ventura R, Maas R, Ruppel R et al (2001) Psychiatric conditions in patients with recurrent unexplained syncope. Europace 3:311–316
Kouakam C, Lacroix D, Klug D et al (2002) Prevalence and prognostic significance of psychiatric disorders in patients evaluated for recurrent unexplained syncope. Am J Cardiol 89:530–535
Linzer M, Pontinen M, Gold DT et al (1991) Impairment of physical and psychosocial function in recurrent syncope. J Clin Epidemiol 44:1037–1043
Linzer M, Gold DT, Pontinen M et al (1994) Recurrent syncope as a chronic disease: preliminary validation of a disease-specific measure of functional impairment. J Gen Intern Med 9:181–185
Rose MS, Koshman ML, Spreng S et al (2000) The relationship between health-related quality of life and frequency of spells in patients with syncope. J Clin Epidemiol 53:1209–1216
Giada F, Silvestri I, Rossillo A et al (2005) Psychiatric profile, quality of life and risk of syncopal recurrence in patients with tilt-induced vasovagal syncope. Europace (in press in press)
Butcher JN, Dahlstrom GW, Graham JR (1989) MMPI-2 manual for administration and scoring. University of Minnesota Press, Minneapolis, p 81
Pancheri P, Sirigatti S (1995) MMPI-2 Minnesota Multiphase Personality Inventory-2 manual. Italian adaptation. OS (Organizzazioni Speciali), Florence, Italy, p 34
Ware JE, Sherbourne CD (1992) The MOS 36-Item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care 30:473–483
Mc-Horney CA, Ware JE, Raczek AE (1993) The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247–263
McGrady AV, Kern-Buell C, Bush E et al (2003) Biofeedback-assisted relaxation therapy in neurocardiogenic syncope: a pilot study. Appl Psychophysiol Biofeedback 28:183–192
Newton JL, Kenny RA, Baker CR (2003) Cognitive behavioural therapy as potential treatment for vasovagal/neurocardiogenic syncope — a pilot study. Europace 5:299–301
Kadri NN, Hee TT, Rovang KS et al (1999) Efficacy and safety of clonazepam in refractory neurally mediated syncope. Pacing Clin Electrophysiol 22:307–314
Ost LG, Hellstrom K, Kaver A (1992) One versus five sessions of exposure in the treatment of injection phobia. Behav Res Ther 23:263–282
Van Dijk N, Velzeboer SCJM, Destree-Vonk A et al (2001) Psychological treatment of malignant vasovagal syncope due to blood phobia. Pacing Clin Electrophysiol 24:122–124
Hellstrom K, Fellenius J, Ost LG (1996) One versus five sessions of applied tension in the treatment of blood phobia. Behav Res Ther 34:101–112
Marks I (1988) Blood-injury phobia: a review. Am J Psychiatry 145:1207–1213
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag Italia
About this chapter
Cite this chapter
Giada, F., Silvestri, I., Rossillo, A., Madalosso, M., Nicotera, P.G., Raviele, A. (2006). Has Psychiatric Treatment Any Role in the Management of Vasovagal Syncope?. In: Raviele, A. (eds) Cardiac Arrhythmias 2005. Springer, Milano. https://doi.org/10.1007/88-470-0371-7_86
Download citation
DOI: https://doi.org/10.1007/88-470-0371-7_86
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0370-5
Online ISBN: 978-88-470-0371-2
eBook Packages: MedicineMedicine (R0)